ProAxsis CEO to present at Sachs Life Science CEO forum
Date : March 01, 2016
Dr David Ribeiro, CEO of ProAxsis, will be attending the Sachs 9th European Life Science CEO forum & exhibition, taking place in Zurich on March 15th-16th 2016, and will be presenting a company update at 09.45h on March 16th. The forum brings together a cross-section of venture-funded and small-cap companies with leading investors, pharmaceutical companies and scientific thought leaders, and is expected to accommodate around 350 delegates.
Dr Ribeiro said: “Forums such as this provide an ideal opportunity for us to continue to publicise the excellent capabilities we have in the capture, detection and measurement of active protease biomarkers of disease. ProAxsis is at a critical stage of its commercial development, with its ProteaseTag™ Active NE Immunoassay now available for researchers, and further assays in late stage development.”
ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.